S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
QTTB · Q32 Bio Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$8.70
+0.06
(+0.75%)
● At close: October 21 at 4:00:00 PM EDT
$8.67
+0.00
(+0.00%)
Overnight:
2:46:16 AM EDT
DAY'S RANGE
$8.70
$8.58
$8.80
52-WEEK RANGE
$8.70
$1.91
$23.57
What's happening
- QTTB is up 0.75% today, trading at $8.70. — Live quote
- Volume today (17,740) is well below its 3-month average of 1,115,990. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.43 actual vs. $-0.55 estimated (+22.2%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 4
Buy 8
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (13 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
QTTB
+159.64%
vs S&P 500
+146.86%
1-YEAR RETURN
QTTB
+158.86%
vs S&P 500
+144.30%
6-MONTH RETURN
QTTB
+50.70%
3-MONTH RETURN
QTTB
-44.06%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.43
Est. $-0.55
BEAT +22.2%
2026-04-26 (Q1 2026)
$-0.54
Est. $-0.69
BEAT +22.1%
2026-01-26 (Q4 2025)
$3.65
Est. $-0.88
BEAT +515.8%
2025-10-26 (Q3 2025)
$-0.60
Est. $-1.21
BEAT +50.5%
Valuation Measures & Ratios
Enterprise Value4$152.7M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)4.82
Price / Book72.04
EV4 / Revenue—
EV4 / EBITDA9.73
Profit Margin107.43%
Operating Margin85.38%
Return on Equity (ROE8)137.41%
Return on Assets (ROA9)45.06%
Avg Volume (3M)1,115,990
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $259.9M | $89.6M | $24.0M | $18.1M | $20.2M |
| P/E | -7.78 | -2.52 | -0.53 | -0.33 | -0.45 |
| Price/Book | 2.45 | 1.94 | -1.30 | -1.48 | -5.04 |
| ROE | -31.57% | -76.69% | 246.66% | 450.29% | 1110.49% |
| ROA | -28.85% | -55.78% | -78.75% | -83.33% | -56.37% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short4,671,943
Change from Prior Settlement+23.84%
% of Float—
Days to Cover (Short Ratio)4.31
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 81.9% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is 107.4%. Finnhub fundamentals ↗
- Trailing 52-week price return is +158.9%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 4, filed 2026-10-14; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on QTTB
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $0 | $0 |
| Operating income | -$9.1M | -$7.7M | -$7.6M | -$9.2M | -$12.2M | -$18.8M | -$17.9M | -$14.8M |
| Net income | -$8.9M | -$7.6M | -$7.4M | -$9.5M | -$11.0M | -$17.6M | -$17.0M | $1.0M |
| EPS (diluted) | $-0.44 | $-0.54 | $-0.60 | $-0.78 | $-0.90 | $-1.46 | $-1.42 | $-6.33 |
| EPS (basic) | $-0.44 | $-0.54 | $-0.60 | $-0.78 | $-0.90 | $-1.46 | $-1.42 | $1.03 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | May '25 | Mar '25 | Dec '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $115.9M | $63.7M | $61.8M | $57.8M | $66.1M | — | $79.1M | $92.3M |
| Total liabilities | $10.0M | $17.4M | $19.8M | $76.2M | $78.4M | — | $83.1M | $86.7M |
| Stockholders' equity | $105.9M | $46.3M | $42.0M | -$18.4M | -$12.2M | $4.0M | -$4.0M | $5.7M |
| Total current assets | $109.6M | $57.2M | $55.0M | $50.8M | $58.3M | — | $68.6M | $81.9M |
| Total current liabilities | $5.4M | $10.7M | $11.3M | $11.1M | $11.5M | — | $14.6M | $16.5M |
| Cash & equivalents | $106.3M | $50.8M | $48.3M | $49.0M | $54.8M | — | $65.5M | $78.0M |
| Marketable securities (current) | — | — | — | — | — | — | — | $0 |
| Other current assets | $19.0K | $20.0K | $20.0K | $24.0K | $77.0K | — | $93.0K | $396.0K |
| Property, plant & equipment | $804.0K | $889.0K | $979.0K | $1.1M | $1.2M | — | $1.3M | $1.4M |
| Other non-current assets | — | — | $0 | $0 | $570.0K | — | $444.0K | $116.0K |
| Accounts payable | $1.6M | $653.0K | $879.0K | $973.0K | $910.0K | — | $2.7M | $3.0M |
| Accrued liabilities | $3.8M | $3.8M | $4.2M | $3.9M | $4.4M | — | $5.3M | $7.5M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Other non-current liabilities | — | — | $0 | $55.0M | $55.0M | — | $55.0M | $55.0M |
| Common stock & paid-in capital | $3.0K | $2.0K | $2.0K | $2.0K | $2.0K | — | $2.0K | $2.0K |
| Retained earnings | -$221.5M | -$212.6M | -$205.0M | -$262.7M | -$255.3M | — | -$245.8M | -$234.8M |
| Accumulated other comprehensive income (loss) | — | — | — | $0 | $0 | — | $0 | $0 |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.1M | -$6.3M | -$6.2M | -$4.2M | -$10.7M | -$12.5M | -$11.4M | -$19.5M |
| Investing cash flow | $0 | $0 | $7.0M | $0 | $0 | $0 | -$2.0K | $9.9M |
| Financing cash flow | $58.6M | $8.8M | -$1.6M | -$1.6M | $0 | — | $317.0K | $997.0K |
| Free cash flow | — | — | -$6.2M | -$4.2M | -$10.7M | — | -$11.4M | -$19.6M |
| Capital expenditures | — | — | $0 | $0 | $0 | — | $2.0K | $58.0K |
| Share-based compensation | $1.7M | $1.5M | $1.5M | $1.2M | $1.3M | $1.3M | $1.3M | $1.4M |
| Deferred income taxes | — | — | — | — | — | — | $100.0K | — |
| Change in accounts payable | $912.0K | -$226.0K | -$94.0K | $63.0K | -$1.8M | -$277.0K | $1.7M | -$1.2M |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Sales/maturities of investments | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $53.7M | $0 | -$6.7M | — | — |
| Operating income | $16.9M | -$66.1M | -$48.3M | -$133.3M | -$95.9M |
| Net income | $29.8M | -$47.7M | -$53.7M | -$5.0M | -$95.8M |
| EPS (diluted) | $2.42 | $-6.58 | $-153.96 | $-0.09 | $-1.73 |
| EPS (basic) | $2.42 | $-5.12 | $-153.96 | $-0.09 | $-1.73 |
| Operating margin | $31 | — | $726 | — | — |
| Net margin | $55 | — | $808 | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $61.8M | $92.3M | $47.1M | $228.5M | $211.7M |
| Total liabilities | $19.8M | $86.7M | $118.5M | $50.5M | $42.1M |
| Stockholders' equity | $42.0M | $5.7M | -$182.9M | -$130.7M | $169.7M |
| Total current assets | $55.0M | $81.9M | $28.7M | $181.0M | $191.9M |
| Total current liabilities | $11.3M | $16.5M | $14.1M | $22.6M | $17.2M |
| Cash & equivalents | $48.3M | $78.0M | $25.6M | $34.0M | $108.4M |
| Marketable securities (current) | — | $0 | $0 | — | — |
| Other current assets | $20.0K | $396.0K | $83.0K | — | — |
| Property, plant & equipment | $979.0K | $1.4M | $1.8M | $1.1M | $2.3M |
| Other non-current assets | $0 | $116.0K | $4.6M | — | — |
| Accounts payable | $879.0K | $3.0M | $3.5M | $1.1M | $2.4M |
| Accrued liabilities | $4.2M | $7.5M | $9.8M | — | — |
| Deferred revenue (current) | — | — | $0 | $1.2M | $3.2M |
| Other non-current liabilities | $0 | $55.0M | $55.0M | — | — |
| Common stock & paid-in capital | $2.0K | $2.0K | $1.0K | $6.0K | $6.0K |
| Retained earnings | -$205.0M | -$234.8M | -$187.1M | -$429.1M | -$424.1M |
| Accumulated other comprehensive income (loss) | — | $0 | $0 | -$404.0K | -$7.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$33.5M | -$67.7M | -$18.7M | -$113.7M | -$109.8M |
| Investing cash flow | $7.0M | $19.9M | -$5.0K | $36.7M | -$50.8M |
| Financing cash flow | -$3.1M | $95.1M | $406.0K | $596.0K | $52.2M |
| Free cash flow | -$33.5M | -$67.8M | -$18.7M | -$114.9M | -$112.1M |
| Capital expenditures | $0 | $75.0K | $5.0K | $1.3M | $2.4M |
| Share-based compensation | $5.3M | $4.4M | $1.4M | $13.1M | $17.2M |
| Deferred income taxes | — | $100.0K | $300.0K | — | — |
| Change in accounts payable | -$2.1M | -$1.0M | $2.0M | -$981.0K | -$2.5M |
| Purchases of investments | — | — | $73.2M | $157.5M | $97.4M |
| Sales/maturities of investments | — | — | $174.2M | $65.5M | $49.0M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding QTTB as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers92.0%
Shares Outstanding23,736,600
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 4,127,987 | $52.6M | 17.39% | +83.2% | 2026-08-14 |
| Boxer Capital Management, LLC | 3,149,310 | $40.1M | 13.27% | +0.0% | 2026-08-14 |
| Atlas Venture Life Science Advisors, LLC | 2,717,106 | $34.6M | 11.45% | +29.9% | 2026-08-13 |
| BVF INC/IL | 2,350,000 | $29.9M | 9.90% | +0.0% | 2026-08-14 |
| RA CAPITAL MANAGEMENT, L.P. | 2,332,457 | $29.7M | 9.83% | +0.0% | 2026-08-14 |
| Point72 Asset Management, L.P. | 1,173,396 | $14.9M | 4.94% | +0.0% | 2026-08-14 |
| Opaleye Management Inc. | 931,000 | $11.9M | 3.92% | -25.9% | 2026-08-14 |
| Logos Global Management LP | 800,000 | $10.2M | 3.37% | +0.0% | 2026-08-14 |
| SummitTX Capital, L.P. | 733,774 | $9.3M | 3.09% | +0.0% | 2026-08-14 |
| VANGUARD CAPITAL MANAGEMENT LLC | 518,803 | $6.6M | 2.19% | +69.3% | 2026-06-30 |
| Ikarian Capital, LLC | 430,000 | $5.5M | 1.81% | +0.0% | 2026-08-14 |
| Woodline Partners LP | 286,212 | $3.6M | 1.21% | +0.0% | 2026-08-14 |
| AMERICAN CENTURY COMPANIES INC | 272,752 | $3.5M | 1.15% | +1353.1% | 2026-08-12 |
| Sanofi | 244,083 | $3.1M | 1.03% | +0.0% | 2026-07-28 |
| ACADIAN ASSET MANAGEMENT LLC | 218,234 | $2.8K | 0.92% | +26.4% | 2026-08-12 |
| ACORN CAPITAL ADVISORS, LLC | 216,171 | $2.8M | 0.91% | -31.4% | 2026-08-14 |
| RENAISSANCE TECHNOLOGIES LLC | 179,600 | $2.3M | 0.76% | -13.2% | 2026-08-13 |
| JANE STREET GROUP, LLC | 162,747 | $2.1M | 0.69% | +148.1% | 2026-08-14 |
| MONIMUS CAPITAL MANAGEMENT, LP | 132,036 | $1.7M | 0.56% | -1.7% | 2026-08-14 |
| BOOTHBAY FUND MANAGEMENT, LLC | 130,427 | $1.7M | 0.55% | +0.0% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 122,690 | $1.6M | 0.52% | +3.8% | 2026-08-12 |
| CITADEL ADVISORS LLC | 120,663 | $1.5M | 0.51% | +679.4% | 2026-08-14 |
| BlackRock, Inc. | 118,507 | $1.5M | 0.50% | +37.6% | 2026-08-07 |
| MARSHALL WACE, LLP | 67,045 | $854.2K | 0.28% | +27.9% | 2026-08-13 |
| VANGUARD FIDUCIARY TRUST CO | 66,217 | $843.6K | 0.28% | +32.4% | 2026-06-30 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-02-24 to 2026-10-06
Recent transactions
- Insiders have net bought 3,727,946 shares over the last 182 days, across 4 purchases and 6 sales.
- Most recent: Morrison Jodie Pope (CEO) — Open market sale of 3,221 shares on 2026-10-06.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)3,750,000 sh(4 txns)
Sales (open market)22,054 sh(6 txns)
Net Shares+3,727,946
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Morrison Jodie Pope | CEO | Open market sale | 2026-10-06 | 3,221 |
| Violette Shelia M. | Chief Scientific Officer | Open market sale | 2026-10-06 | 917 |
| Kalowski Lee | CFO and President | Open market sale | 2026-10-06 | 1,301 |
| Manke Isaac | Reporting person | Option exercise | 2026-06-30 | 53,521 |
| Xu Diyong | Director | Open market purchase | 2026-05-28 | 1,250,000 |
| ORBIMED ADVISORS LLC | Director | Open market purchase | 2026-05-28 | 1,250,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-06 | Morrison Jodie Pope | CEO | Open market sale | 3,221 | $8.32 |
| 2026-10-06 | Violette Shelia M. | Chief Scientific Officer | Open market sale | 917 | $8.32 |
| 2026-10-06 | Kalowski Lee | CFO and President | Open market sale | 1,301 | $8.32 |
| 2026-08-25 | Morrison Jodie Pope | CEO | Open market sale | 9,845 | $16.56 |
| 2026-08-25 | Kalowski Lee | CFO and President | Open market sale | 3,972 | $16.56 |
| 2026-08-25 | Violette Shelia M. | Chief Scientific Officer | Open market sale | 2,798 | $16.56 |
| 2026-07-16 | Violette Shelia M. | Chief Scientific Officer | Grant / award | 37,500 | $0.00 |
| 2026-07-16 | Morrison Jodie Pope | CEO | Grant / award | 132,000 | $0.00 |
| 2026-07-16 | Kalowski Lee | CFO and President | Grant / award | 53,250 | $0.00 |
| 2026-06-30 | Manke Isaac | Reporting person | Option exercise | 53,521 | $2.80 |
| 2026-05-28 | Xu Diyong | Director | Open market purchase | 1,250,000 | $8.00 |
| 2026-05-28 | Xu Diyong | Director | Open market purchase | 625,000 | $8.00 |
| 2026-05-28 | ORBIMED ADVISORS LLC | Director | Open market purchase | 1,250,000 | $8.00 |
| 2026-05-28 | ORBIMED ADVISORS LLC | Director | Open market purchase | 625,000 | $8.00 |
| 2026-02-25 | Kalowski Lee | CFO and President | Open market sale | 3,995 | $4.51 |
| 2026-02-25 | Morrison Jodie Pope | CEO | Open market sale | 9,896 | $4.51 |
| 2026-02-24 | Violette Shelia M. | Chief Scientific Officer | Grant / award | 37,500 | $0.00 |
| 2026-02-24 | Morrison Jodie Pope | CEO | Grant / award | 132,000 | $0.00 |
| 2026-02-24 | Kalowski Lee | CFO and President | Grant / award | 53,250 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 07:05 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-14 | 4 | 2026-10-06 | View on SEC.gov → |
| 2026-10-14 | 4 | 2026-10-06 | View on SEC.gov → |
| 2026-10-14 | 4 | 2026-10-06 | View on SEC.gov → |
| 2026-09-30 | 8-K | 2026-09-30 | View on SEC.gov → |
| 2026-09-14 | 8-K | 2026-09-14 | View on SEC.gov → |
| 2026-08-27 | 4 | 2026-08-25 | View on SEC.gov → |
| 2026-08-27 | 4 | 2026-08-25 | View on SEC.gov → |
| 2026-08-27 | 4 | 2026-08-25 | View on SEC.gov → |
| 2026-08-05 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-05 | 8-K | 2026-08-05 | View on SEC.gov → |
| 2026-07-20 | 4 | 2026-07-16 | View on SEC.gov → |
| 2026-07-20 | 4 | 2026-07-16 | View on SEC.gov → |
Recent news
Headlines about QTTB (Q32 Bio Inc.). Links open the publisher — we don’t host full articles.
-
Why Did AAPL, QTTB, CSX Stocks Surge To 52-Week Highs Today?
Stocktwits · 2026-10-19 -
Technical Reactions to QTTB Trends in Macro Strategies
Stock Traders Daily · 2026-10-18 -
QTTB Apr 2027 30.000 call (QTTB270416C00030000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-18 -
QTTB Nov 2026 7.500 put (QTTB261120P00007500) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-17 -
QTTB Nov 2026 7.500 put (QTTB261120P00007500) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-16 -
Leerink Partners Initiates Coverage On Q32 Bio with Outperform Rating, Announces Price Target of $40
Benzinga · 2026-10-12 -
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
Yahoo Finance · 2026-09-30 -
Q32 Bio: Durable Hair Regrowth Remains The Goal
Seeking Alpha · 2026-09-26
No headlines in this category right now — try “All”.